drugset / Trial / NCT05282771
A Study Comparing Halobetasol Propionate and Tazarotene Topical Lotion 0.01%/0.045% to Duobrii® Lotion (Halobetasol Propionate and Tazarotene Lotion), 0.01%/0.045% (Reference Listed Drug) in the Treatment of Moderate to Severe Plaque Psoriasis.
RandomizedParallel-groupSingle-blindTreatment
Summary
To evaluate the therapeutic equivalence and safety of halobetasol propionate and tazarotene topical lotion 0.01%/0.045% (Taro Pharmaceuticals U.S.A., Inc.) and Duobrii® Lotion (halobetasol and tazarotene lotion), 0.01%/0.045% (Reference Listed Drug) in the treatment of moderate to severe plaque psoriasis.
Timeline
- Start
- 2021-04-16
- Primary completion
- 2022-02-10
- Completion
- 2022-02-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Duobrii | Unknown | 0.01 % | Topical |
| Comparator | Duobrii | Unknown | 0.045 % | Topical |
| Subject | halobetasol propionate | Small molecule | 0.01 % | Topical |
| Subject | halobetasol propionate | Small molecule | 0.045 % | Topical |